What question did this study set out to answer?

The study aims to elucidate how SPOP mutations and CHD1 deletions influence ferroptosis sensitivity in prostate cancer.

Divergent Roles of SPOP and CHD1 in Ferroptosis Regulation in Prostate Cancer

View Full Paper

Ask AI

Bookmark

The study aims to elucidate how SPOP mutations and CHD1 deletions influence ferroptosis sensitivity in prostate cancer.
Utilized engineered human cell lines and 3D organoid systems
Employed genetically engineered mouse models and isogenic xenografts
Conducted lipid peroxidation assays and pharmacologic GPX4 inhibition
Performed transcriptomic, lipidomic, and biochemical analyses including ChIP-seq
Assessed MYC-ACSL4 transcriptional axis via luciferase reporter assays
SPOP mutations increase sensitivity to GPX4 inhibition while CHD1 loss leads to resistance
SPOP mutations enhance MYC occupancy and ACSL4 transcriptional activation
Pharmacologic blockade of cholesterol biosynthesis restores ferroptosis sensitivity in SPOP-mutant/CHD1-deficient tumors
Identified a targetable metabolic checkpoint for overcoming ferroptosis resistance in specific prostate cancer subtypes

No takes yet. Share an insight, caveat, or question.

This research uncovers divergent roles of SPOP and CHD1 in regulating ferroptosis, indicating new therapeutic strategies for prostate cancer.

Chen et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

This research uncovers divergent roles of SPOP and CHD1 in regulating ferroptosis, indicating new therapeutic strategies for prostate cancer.